Abiopharma

🔍 Meury William (Director)

Company: INCYTE CORP (INCY)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 125,000 shares of Common Stock (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 161,101.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 15, 2026. The earned shares will vest on July 2, 2026, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive up to 400% of one share of common stock. The number of shares that may be earned and vested is contingent on the achievement of pre-established performance and vesting conditions over a six-year performance period, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2025. Although the Issuer is obligated to issue these earned shares to the Reporting Person, these shares will settle and be delivered to the Reporting Person on June 26, 2028, the third anniversary of the commencement of his employment with the Issuer.
• F2: This includes an aggregate of 161,101 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.